Clinical Trial Update: Dendritic Cell Vaccine Study (DC/PC3) for Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a dendritic cell vaccine (DC/PC3) for prostate cancer has completed, with results posted in 2016. The sponsor listed is Ro…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• DC/PC3 Dendritic Cell Vaccine (dendritic cell vaccine loaded with PC3 prostate cancer cells (DC/PC3))

Snippet

Sponsor: Rockefeller University | Conditions: Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2016-04-18